MRG003治疗组与对照组生存率对比分析

As of June 30, 2024, the number of deaths in the MRG003 treatment group and the control group were 26 (28.1%) and 28 (24.1%), respectively. The median overall survival (OS) was NR (95% CI: 9.63, NE) and NR (95% CI: 10.22, NE), respectively (HR = 0.84; 95% CI: 0.49, 1.44; log-rank P = 0.5528). As of December 30, 2024, the median follow-up times for the experimental group and the control group were 13.47 months and 13.63 months, respectively. The number of deaths in the MRG003 treatment group was 39 (45.3%), with a median OS of 17.08 months (95% CI: 11.43, NE). In the control group, the number of deaths was 48 (55.2%), with a median OS of 11.99 months (95% CI: 9.69, 15.44). There was no statistically significant difference in OS between the two groups (HR = 0.73; 95% CI: 0.48, 1.12) (Figure 2C). Sensitivity analysis of OS showed that after censoring patients who crossed over to MRG003 treatment, the median OS for the two groups was 17.08 months (95% CI: 11.43, NE) and 11.10 months (95% CI: 8.54, NE), respectively. Treatment with MRG003 significantly reduced the risk of death (HR = 0.59; 95% CI: 0.37, 0.93; log-rank P = 0.0204).